|Mr. Dario Eklund||Chief Exec. Officer||731.41k||N/A||1968|
|Dr. Thomas Meier Ph.D.||Founder & Director||97.18k||N/A||1962|
|Mr. Andrew P. Smith||Chief Financial Officer||479.45k||N/A||1963|
|Mr. Oliver Strub||Exec. VP, Gen. Counsel & Sec.||N/A||N/A||1963|
|Mr. GÃ¼nther Metz||Head of Bus. Devel. & Exec. VP||N/A||N/A||1958|
|Eva Kalias||Head of External Communications||N/A||N/A||N/A|
|Mr. Shabir Hasham||Head of the Puldysa Global Program||N/A||N/A||N/A|
|Ms. Stephanie Brown B.Sc., M.B.A.||Pres of North America||N/A||N/A||N/A|
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. It is developing Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage, or age. The company's late stage drug candidate include vamorolone, which is being developed as treatments for DMD. Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies. The company also out-licenses ex-North American rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. It has collaboration agreement with Cold Spring Harbor Laboratory to investigate the potential of lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase, as a therapeutic intervention for COVID-19-related acute respiratory distress syndrome. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland.
Santhera Pharmaceuticals Holding AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.